GLP-1 Medications and Surgery: Perioperative Safety Guide
Should you stop GLP-1 medications before surgery? New 2024–2025 multi-society guidance on aspiration risk, 24-hour liquid diet, and what to tell your anesthesiologist.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on May 5, 2026
Our medical review process ensures clinical accuracy and patient safety.
Introduction
If you take a GLP-1 receptor agonist such as semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Saxenda, Victoza), or tirzepatide (Mounjaro, Zepbound) and you are scheduled for surgery or an endoscopy, the question every patient now asks is the same: should I stop the medication before the procedure?
The answer changed substantially between 2023 and 2025. Early guidance was conservative — hold the drug for one full dosing interval (up to a week for weekly formulations). Updated multi-society guidance from October 2024 walks that back: most patients can continue their GLP-1 therapy, provided they follow a 24-hour clear-liquid diet before anesthesia and their anesthesiologist is aware of the medication.
The driver of all this guidance is a single mechanism — delayed gastric emptying — and the question of how often it leads to retained food in the stomach at the moment of induction, when the airway reflexes are blunted and aspiration of stomach contents into the lungs becomes possible.
This article walks through what the imaging studies actually show, what the current consensus statements recommend, and what to discuss with your surgical and anesthesia team.
Why GLP-1 Medications Are a Perioperative Concern
GLP-1 receptor agonists slow gastric emptying as part of how they reduce appetite and post-meal blood glucose. That same effect — desirable for weight loss — means food can remain in the stomach longer than the standard 6–8 hour fasting window assumes. Under general anesthesia, retained gastric contents can be regurgitated and aspirated into the lungs, a complication associated with pneumonitis, pneumonia, and rare but catastrophic outcomes.
The clinical question is not whether GLP-1 drugs delay gastric emptying — they do. The question is how often that translates to clinically meaningful residual gastric content (RGC) after a standard preoperative fast, and whether that residual content actually increases aspiration events.
Evidence: "Increased residual gastric content was observed in 27 (6.7%) patients overall, with 8 (24.2%) in the semaglutide group and 19 (5.1%) in the non-semaglutide group (p < 0.001)." — Silveira SQ, et al. J Clin Anesth. 2023. DOI: 10.1016/j.jclinane.2023.111091
What the Imaging and Endoscopy Studies Show
Three lines of evidence have shaped the current guidelines: gastric ultrasound studies, endoscopy studies, and pooled meta-analyses.
Gastric Ultrasound
Point-of-care gastric ultrasound directly visualizes the antrum and can classify stomach contents as empty, clear fluid, or solid. In a prospective controlled study of volunteers recently started on semaglutide, solid contents were detected on ultrasound in the majority of users despite a standard 8-hour fast.
Evidence: "In the supine position, 70% of semaglutide participants and 10% of control participants had solids present on gastric ultrasound, and in the lateral position, 90% versus 20% had solids identified." — Sherwin M, et al. Can J Anesth. 2023. DOI: 10.1007/s12630-023-02549-5
A larger prospective observational study confirmed the signal in a real perioperative population.
Evidence: "Increased residual gastric content was found in 43 of 107 patients (40%) in the semaglutide group versus 3 of 113 (3%) in the non-semaglutide group." — Nersessian RSF, et al. Anaesthesia. 2024. DOI: 10.1111/anae.16454
Endoscopy Cohorts
Upper endoscopy provides direct visualization of the stomach and is, in effect, a much larger natural experiment for retained contents. Pooled across studies, the signal is consistent: GLP-1 RA users have several-fold higher odds of retained gastric content at the time of the procedure, even after standard fasting.
Evidence: "Pooled analysis showed GLP-1 receptor agonist use was associated with significantly higher rates of retained gastric content compared with non-users (OR 5.57; 95% CI 4.07–7.62)." — Hiramoto B, et al. Gastrointestinal Endoscopy. 2024. DOI: 10.1016/j.gie.2024.05.040
The translation to actual aspiration events, however, is far less clear. Aspiration is rare in the modern operating room — under 0.2% of cases — and most pooled analyses have not detected a statistically significant rise in aspiration rates among GLP-1 users, despite the higher rate of retained contents. The most common downstream consequence is procedural delay, modification, or cancellation rather than aspiration injury.
Risk Modifiers
Not every patient on a GLP-1 carries the same risk. Across the imaging and endoscopy literature, three modifiable factors keep emerging:
| Risk Factor | Effect on Retained Gastric Content |
|---|---|
| Dose-escalation phase (first weeks–months) | Higher residual content; gastric emptying effect is most pronounced before tolerance develops |
| Higher dose (e.g., semaglutide 2.4 mg, tirzepatide 15 mg) | Dose-dependent increase in residual content |
| Weekly long-acting formulations | Greater steady-state exposure than short-acting daily drugs |
| Active GI symptoms (nausea, fullness, reflux) | Independent predictor of residual content |
A patient on a stable maintenance dose for a year with no GI symptoms is in a very different risk bucket than a patient three weeks into dose escalation who still feels full at bedtime.
What the 2024–2025 Guidelines Actually Say
The 2023 ASA Position (Now Outdated as Standalone Advice)
The original 2023 American Society of Anesthesiologists guidance recommended holding GLP-1 RAs for one dosing interval before elective procedures — daily formulations skipped on the day of surgery, weekly formulations skipped for one week. That blanket "hold the drug" approach is no longer the prevailing recommendation.
The October 2024 Multi-Society Guidance
In October 2024, five major societies — the ASA, American Gastroenterological Association (AGA), American Society for Metabolic and Bariatric Surgery, International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons — issued joint guidance that materially changed the standard.
Evidence: "Patients without elevated risk for delayed gastric emptying may continue GLP-1 RAs perioperatively. Patients at higher risk should follow a 24-hour clear-liquid diet prior to the procedure to mitigate aspiration risk." — Kindel TL, et al. Multisociety Clinical Practice Guidance. Clin Gastroenterol Hepatol. 2024. DOI: 10.1016/j.cgh.2024.10.003
The shift reflects three points: (1) routinely stopping a chronic obesity or diabetes medication carries its own metabolic costs; (2) most aspiration events do not occur even when retained content is present; and (3) a 24-hour liquid diet is a far less disruptive intervention than discontinuing a long-acting drug for a week.
The AGA Endoscopy Update
For endoscopic procedures specifically, the AGA had already issued a rapid clinical practice update suggesting that, when concerns about retained contents arise, the response should be procedure-level — using ultrasound assessment, considering rapid-sequence intubation, or modifying sedation — rather than blanket discontinuation of effective therapy.
Evidence: "Decisions on continuing or holding GLP-1 RAs prior to endoscopy should be individualized based on patient-specific factors and procedural considerations rather than applying universal hold protocols." — Hashash JG, et al. AGA Rapid Clinical Practice Update. Clin Gastroenterol Hepatol. 2024. DOI: 10.1016/j.cgh.2023.11.002
International Consensus
UK and European multi-society consensus statements published through 2024 and 2025 broadly converged on the same framework: continue therapy in low-risk patients, extend the liquid-only fast in higher-risk patients, and use bedside gastric ultrasound when uncertainty remains.
Evidence: "GLP-1 receptor agonists should not be routinely discontinued before elective surgery in low-risk patients; perioperative management should be individualized through shared decision-making." — Idris I, et al. Diabetes Obes Metab. 2024. DOI: 10.1002/doi2.70009
A Practical Risk-Stratified Framework
Putting the evidence together, the current standard of care looks roughly like this:
| Patient Profile | Suggested Approach |
|---|---|
| Stable maintenance dose, no GI symptoms, elective low-risk surgery | Continue GLP-1; standard 8-hour fast from solids; clear liquids up to 2 hours before |
| Dose-escalation phase, weekly drug, or higher dose | Continue GLP-1; extend to 24-hour clear-liquid diet before anesthesia |
| Active nausea, vomiting, fullness, or reflux | Hold dose if feasible; consider preoperative gastric ultrasound; treat as full stomach |
| Emergency surgery on a GLP-1 user | Treat as full stomach regardless of fasting time; consider rapid-sequence intubation |
| Endoscopy specifically | Individualized per AGA guidance; 24-hour liquid diet often preferred to drug discontinuation |
A "full stomach" precaution typically means rapid-sequence induction with cricoid pressure, awake or video-assisted intubation, and avoiding mask ventilation that could insufflate the stomach. These are routine, well-validated techniques in anesthesia.
For background on the broader side-effect profile of GLP-1 medications and on the gastric symptoms many users experience, the perioperative recommendations build directly on the same delayed-emptying mechanism.
What to Tell Your Surgical and Anesthesia Team
Before any procedure requiring sedation or general anesthesia, your care team needs four pieces of information:
- The drug name and dose. Semaglutide 2.4 mg weekly is a different exposure than liraglutide 1.2 mg daily.
- How long you have been on therapy and at the current dose. Recent dose escalation is the single biggest risk amplifier.
- When the last dose was administered. For weekly formulations, this anchors how much active drug remains at the time of induction.
- Whether you have had any GI symptoms — nausea, vomiting, early satiety, reflux, or feeling that food is "sitting" in the stomach.
Do not stop a GLP-1 medication on your own without confirming the plan with both the prescribing clinician and the anesthesia team. For diabetes patients, abrupt discontinuation can produce hyperglycemia; for chronic obesity treatment, even a one-dose gap can disrupt appetite control.
Special Considerations
Bariatric Surgery
GLP-1 therapy before metabolic and bariatric surgery is now common, both as a bridge and as long-term adjunctive therapy. Society guidance generally supports continuation in this population with the same liquid-diet precautions, since these patients are already on protocolized perioperative pathways with anesthesia teams familiar with high-risk gastric anatomy.
Pregnancy and Lactation
GLP-1 medications are not currently recommended in pregnancy. If you are taking a GLP-1 drug and become pregnant before a planned procedure, the medication will typically be discontinued for reasons unrelated to anesthesia risk — discuss with your obstetric and prescribing teams.
Pediatric Patients
The October 2024 multi-society guidance explicitly extends to pediatric and adolescent patients on GLP-1 therapy for obesity, with the same 24-hour liquid-diet recommendation for higher-risk profiles.
Endoscopy Without General Anesthesia
For procedures done under conscious sedation rather than general anesthesia (e.g., many colonoscopies), the airway-protection rationale weakens, but retained gastric contents can still cause procedural difficulty and a higher rate of aborted exams.
Key Takeaways
- GLP-1 receptor agonists clearly delay gastric emptying and increase residual gastric content at the time of induction, with effect sizes around a 4–6 fold higher odds in pooled analyses.
- Actual pulmonary aspiration events remain rare (≤0.2%) and not consistently elevated in GLP-1 users when modern anesthesia precautions are used.
- Current 2024–2025 multi-society guidance recommends continuing GLP-1 therapy in low-risk patients, with a 24-hour clear-liquid diet for higher-risk profiles, rather than blanket drug discontinuation.
- Risk is highest during dose escalation, on weekly long-acting formulations, at higher doses, and when GI symptoms are present.
- Always disclose the drug, dose, last administration, and any GI symptoms to the anesthesia team — and never stop the medication unilaterally without coordinating with prescriber and surgical team.
The conservative answer of a few years ago — "hold every GLP-1 for a week before any anesthesia" — is no longer the standard. The contemporary answer is more nuanced and, in most cases, lets patients keep the metabolic benefits of therapy while still protecting the airway through fasting strategy and anesthetic technique.
References
- Silveira SQ, da Silva LM, de Campos Vieira Abib A, et al. Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth. 2023;87:111091. DOI: 10.1016/j.jclinane.2023.111091
- Sherwin M, Hamburger J, Katz D, DeMaria S Jr. Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide. Can J Anaesth. 2023;70(8):1300-1306. DOI: 10.1007/s12630-023-02549-5
- Nersessian RSF, Abib ACV, Mello LSCC, et al. Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study. Anaesthesia. 2024;79(12):1301-1309. DOI: 10.1111/anae.16454
- Kindel TL, Wang AY, Wadhwa A, et al. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Clin Gastroenterol Hepatol. 2024;22(11):2289-2293. DOI: 10.1016/j.cgh.2024.10.003
- Hashash JG, Thompson CC, Wang AY. AGA rapid clinical practice update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: communication. Clin Gastroenterol Hepatol. 2024;22(4):705-707. DOI: 10.1016/j.cgh.2023.11.002
- Hiramoto B, Flanagan R, Muftah M, et al. Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and meta-analysis. Gastrointest Endosc. 2024;100(5):885-895. DOI: 10.1016/j.gie.2024.05.040
- Idris I, Hartley P, Whyte M, et al. Multi-society consensus guidance on handling of GLP-1 therapy prior to general anaesthesia. Diabetes Obes Metab. 2024. DOI: 10.1002/doi2.70009
Last updated: 2026-05-05 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.